CD52 and acute lymphoblastic leukemia: CD19+ r/r B-ALL patients received lymphodepleting chemotherapy, anti-CD52 serotherapy (alemtuzumab), and 1 dose of TCR– CD52– CAR19 T cells that established molecular remission within 28 days without GVHD which persisted until conditioning before allo-SCT [57, 115, 116].